A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Article uri icon

Overview

authors

  • Korde, Neha
  • Carlsten, Mattias
  • Lee, Min-Jung
  • Minter, Alex
  • Tan, Esther
  • Kwok, Mary
  • Manasanch, Elisabet
  • Bhutani, Manisha
  • Tageja, Nishant
  • Roschewski, Mark
  • Zingone, Adriana
  • Costello, Rene
  • Mulquin, Marcia
  • Zuchlinski, Diamond
  • Maric, Irina
  • Calvo, Katherine R
  • Braylan, Raul
  • Tembhare, Prashant
  • Yuan, Constance
  • Stetler-Stevenson, Maryalice
  • Trepel, Jane
  • Childs, Richard
  • Landgren, Ola

publication date

  • March 21, 2014

Research

keywords

  • Antibodies, Monoclonal
  • Multiple Myeloma
  • Receptors, KIR

Identity

PubMed Central ID

  • PMC4040899

Scopus Document Identifier

  • 84901712243

Digital Object Identifier (DOI)

  • 10.3324/haematol.2013.103085

PubMed ID

  • 24658821

Additional Document Info

volume

  • 99

issue

  • 6